Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00625820 · ClinicalTrials.gov registry record · Phase 2
Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria
A Phase 2 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00625820 is a Phase 2 study that has completed, run by University of Michigan. The registered enrollment target is 17 participants.
The verdict
NCT00625820, a Phase 2 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
Patients with chronic kidney disease (CKD) and albuminuria are at increased risk of developing cardiovascular disease (CVD) which is often associated with hypertension, left ventricular hypertrophy, endothelial dysfunction and increased generation of reactive oxygen species (ROS). These patients also manifest a decrease in nitric oxide (NO) availability which is thought to play an important role in their progressive vascular disease. Tetrahydrobiopterin (BH4), an essential cofactor for endothelial nitric oxide synthase(eNOS), an important regulator of NO and that is a key mediator of endothelial dysfunction. Changes in NO availability are believed to contribute to endothelial dysfunction seen in CKD and common CVD states. 6R-tetrahydrobiopterin (6R-BH4 or sapropterin dihydrochloride) is an investigational oral drug that is being evaluated to determine whether it will restore NO availability, leading to beneficial effects on vascular function and ultimately positive clinical outcomes in patients with CKD. The primary endpoint in this study is the level of albuminuria, an easily measured marker that has served as a predictor of kidney disease progression. If 6R-BH4 reduces albuminuria in patients with kidney disease, it may have implications to slow the disease progression as well as decreased risk of CVD.
Interventions
- DIETARY_SUPPLEMENT Vitamin C
- DRUG 6R BH4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2008-05 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00625820
The ClinicalTrials.gov registry entry for NCT00625820 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vitamin C is the first listed.
NCT00625820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00625820 about?
NCT00625820 is a clinical study titled "Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria". Patients with chronic kidney disease (CKD) and albuminuria are at increased risk of developing cardiovascular disease (CVD) which is often associated with hypertension, left ventricular hypertrophy, endothelial dysfunction and increased generation of reactive oxygen species (ROS). These patients als...
What is the current status of trial NCT00625820?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2008-05. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00625820?
The interventions under investigation include: Vitamin C (DIETARY_SUPPLEMENT), 6R BH4 (DRUG).
Who is sponsoring clinical trial NCT00625820?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.